You are here: Industry Insights > WuXi AppTec

News List

Pharmaceutical Enterprises to be Listed in China in 2018 Caicai
May 09, 2018
Let me tell you something horrible today: please see the “progress bar” of 2018 which is about to reach 1/3.
Pharma-tech Company WuXi AppTec announces its IPO biospectrumasia
May 09, 2018
in Share .    The medical device company lists its initial public offering (IPO) of 104,198,600 shares of common stock, at a public offering price of RMB 21.60 per share
Why Chinese CROs, low-key all the time, financed in a high-key manner in 2017? Sinohealth
May 04, 2018
Contract research organization rose at the beginning of 1980s. The rise of the Chinese CRO industry was more than a decade later than the Europe and America
WuXi AppTec to expand drug development testing services biospectrumasia
April 23, 2018
The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein
RMB 5.741 Billion to Raise! The Second Unicorn This Year—CRO Dominant Wuxi AppTec to be Listed on Shanghai Stock Exchange Caicai
April 11, 2018
WuXi AppTec Co., Ltd. was in the IPO list on March 27, with the intention to be listed on Shanghai Stock Exchange and raise fund of about RMB 5.741 billion. If everything goes well, it will be successfully listed next week, being the second unicorn listed
Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel worldpharmanews
March 01, 2018
Merck announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel.
WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Lead prnasia
October 09, 2017
The award is part of the Frost & Sullivan Best Practices Award series, which recognizes best-in-class companies that have demonstrated excellence in their respective industries.
WuXi AppTec Completes Acquisition of HD Biosciences en-cphi.cn
May 16, 2017
WuXi AppTec announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
WuXi AppTec Bioanalytical Service Unit Passes FDA Inspection contractpharma
March 02, 2017
Shanghai facility successfully completes audit and bioequivalence inspection

Previous page 1 2 3 Next page